Engineered Bacteria Offer Novel Approach to Targeting Solid Tumors, Dr. Martha Boeckenfeld Reports

In a recent LinkedIn post, Dr. Martha Boeckenfeld discusses a groundbreaking, decade-long research effort into using engineered bacteria to treat solid tumors, highlighting a novel approach to overcoming treatment resistance in the “necrotic center” of these cancers.

Dr. Boeckenfeld introduces the challenge posed by the oxygen-depleted core of solid tumors, a region where conventional treatments like radiation often falter. This dead zone, she explains, can be a significant reason why treatments eventually stop working for patients.

“Inside a solid tumor, there is a place treatment struggles to reach. The core runs out of oxygen. Cells die and pile up. Radiation weakens before it gets there. Doctors call it the necrotic center.”

Harnessing Nature’s Design for Cancer Therapy

The core of Dr. Boeckenfeld’s report centers on the work of Sara Sadr, a doctoral student at the University of Waterloo, and her collaborator Bahram Zargar. Their research question was ambitious: could a naturally occurring bacterium, Clostridium sporogenes, which thrives in oxygen-absent environments, be engineered to colonize the necrotic center of tumors?

As Dr. Boeckenfeld notes, these bacteria’s spores can naturally migrate to oxygen-free tumor zones and multiply. The potential impact is significant, given that 80 to 90% of adult cancers are solid tumors, including common types like breast, lung, prostate, colon, and pancreatic cancers.

Overcoming the Edge Problem: A Genetic Switch

A key hurdle identified in the research was the bacteria’s vulnerability in the oxygen-rich outer rim of the tumor, where they tended to die. To address this, Sadr engineered a critical “genetic switch.” This mechanism, activated by a “crowd sensor” (an aerotolerance gene called noxA), allows the bacteria to survive at the tumor’s edge only when they have gathered in sufficient numbers.

Dr. Boeckenfeld explains the elegant logic of this system:

“The bacteria detect their own numbers, turn on the switch, and survive at the oxygen-rich edge. In healthy tissue, where oxygen flows freely and bacteria are too spread out, the switch stays off. The bacteria die.”

This ingenious design ensures the bacteria are active within the tumor’s core and only expand to the edges under specific, controlled conditions. Furthermore, once their work is done, the natural oxygen levels in the bloodstream are designed to neutralize the bacteria.

Preclinical Promise and Future Directions

It is crucial to note, as Dr. Boeckenfeld emphasizes, that this research is still in the preclinical stage, involving lab and animal models. Human trials are estimated to be three to five years away and contingent on further funding. The project represents a significant investment of over a decade of work across multiple institutions.

Dr. Boeckenfeld also points to the broader context of this research, referencing a 2026 PLOS Biology study that explored a similar concept using engineered probiotic E. coli. She quotes the team’s applied mathematician, Brian Ingalls, who analogized the DNA circuits to sophisticated electrical systems:

“Input. Logic. Output. Except the wires are alive.”

The article concludes by posing a reflective question to the audience about persistent problems in their own work or lives, drawing a parallel to the decade-long pursuit of this innovative cancer treatment strategy.